REQUEST A DEMO
Total
USD $0.00
Search more companies

Astellas Pharma Korea, Inc. (South Korea)

Main Activities: Drugs and Druggists' Sundries Merchant Wholesalers
Full name: Astellas Pharma Korea, Inc. Profile Updated: December 24, 2024
Buy our report for this company USD 29.95 Most recent financial data: 2022 Available in: English Download a sample report

Astellas Pharma Korea, Inc. is an enterprise in South Korea, with the main office in Seoul. It operates in the Drugs and Druggists' Sundries Merchant Wholesalers industry. The company was established on August 01, 1994. It currently has a total number of 175 (2024) employees. From the latest financial highlights, Astellas Pharma Korea, Inc. reported a net sales revenue drop of 7.23% in 2022. A negative growth of 18.53% was recorded in its total assets. In, 2022, the company’s net profit margin decreased by 0.58%.

Headquarters
7th Floor, 521, Teheran-ro Gangnam-gu Seoul
Seoul; Seoul; Postal Code: 135090

Contact Details: Purchase the Astellas Pharma Korea, Inc. report to view the information.

Website: http://www.astellas.com/kr

Basic Information
Total Employees:
Purchase the Astellas Pharma Korea, Inc. report to view the information.
Outstanding Shares:
Purchase the Astellas Pharma Korea, Inc. report to view the information.
Registered Capital:
Purchase the Astellas Pharma Korea, Inc. report to view the information.
Incorporation Date:
August 01, 1994
Key Executives
Purchase this report to view the information.
CEO
Ownership Details
Purchase this report to view the information.
100%
Company Performance
Financial values in the chart are available after Astellas Pharma Korea, Inc. report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency KRW. Absolute financial data is included in the purchased report.
Net sales revenue
-7.23%
Total operating revenue
-7.23%
Operating profit (EBIT)
-9.5%
EBITDA
-11.34%
Net Profit (Loss) for the Period
-19.84%
Total assets
-18.53%
Total equity
12.01%
Operating Profit Margin (ROS)
-0.15%
Net Profit Margin
-0.58%
Return on Equity (ROE)
-4.26%
Quick Ratio
0.28%
Cash Ratio
0.22%

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?